Literature DB >> 10590912

Supply, use, and abuse of intravenous immunoglobulin.

A Nowak-Wegrzyn1, H M Lederman.   

Abstract

Intravenous immunoglobulin is used as a replacement therapy in primary immunodeficiency diseases as well as an immunomodulatory agent in a variety of autoimmune and inflammatory disorders. The mechanisms of intravenous immunoglobulin action are complex and, for some disorders, not well understood. This paper reviews the recent literature and discusses approved, new, and controversial indications for intravenous immunoglobulin therapy, with special emphasis on its mechanism of action.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10590912     DOI: 10.1097/00008480-199912000-00011

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  4 in total

1.  Flebogamma(®) 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases.

Authors:  Mark Ballow; Paul J Pinciaro; Timothy Craig; Gary Kleiner; James Moy; Hans D Ochs; John Sleasman; William Smits
Journal:  J Clin Immunol       Date:  2016-06-08       Impact factor: 8.317

2.  Comparative Study of Two ELISA Kits for Estimation of Antibodies to Hepatitis B Virus in Human Normal Immunoglobulin and Specific Immunoglobulin Intended for Intravenous or Intramuscular Use.

Authors:  J P Prasad; Y Madhu; Arushi Mandhan; Payal Garg; Anu Prakash; Varsha Singh; Daud Ali; Prdeep Kumar; Surinder Singh; G R Soni; Varun Singh
Journal:  Indian J Clin Biochem       Date:  2016-06-29

3.  Efficacy and tolerability of an argentine intravenous immunoglobulin in pediatric patients with primary immunodeficiency diseases.

Authors:  S Krasovec; A Ornani; M Oleastro; S Rosenzweig; A Roy; L Perez; G Campos; N Marín; A Martinez; C Mahieu; M J Manfredi; A Sisti; M Zelazko
Journal:  J Clin Immunol       Date:  2007-01-19       Impact factor: 8.317

4.  The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease.

Authors:  Shreeram Akilesh; Stefka Petkova; Thomas J Sproule; Daniel J Shaffer; Gregory J Christianson; Derry Roopenian
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.